When most people think of acute diarrheal infections, they picture spoiled picnic food, contaminated tap water during travel, or a stomach bug in a daycare. Yet infectious disease specialists and public health agencies are tracking a significant shift in how one common enteric pathogen spreads.
Shigella, a bacterium notorious for causing inflammatory dysentery, is increasingly circulating as a sexually transmitted infection. More critically, genomic surveillance in The Lancet Infectious Diseases and reports from the Centers for Disease Control and Prevention (CDC) show that these strains carry high rates of antimicrobial resistance—including extensively drug-resistant (XDR) variants that resist standard first-line antibiotics.
Recognizing how this bacterium spreads, identifying symptoms early, and following evidence-based precautions are vital for digestive and community health.
What Is Shigella and How Does It Spread Sexually?
Shigellosis is an acute intestinal infection caused by Shigella bacteria. According to the CDC, Shigella has an exceptionally low infectious dose: as few as 10 to 100 bacterial cells can trigger clinical illness.
While historically spread through contaminated food or water, this minute infectious threshold allows efficient transmission via fecal-oral exposure during intimacy. Transmission occurs through direct oral-anal contact, digital-anal contact, or indirect transfer via hands, condoms, and sex toys. Because bacteria are microscopic, routine washing immediately before or after sex does not reliably eliminate the small inoculum needed to cause illness.
Hallmark Symptoms and Clinical Course
Symptoms generally emerge within 1 to 2 days following exposure:
- Severe Diarrhea: Watery stools frequently progressing to dysentery with visible blood and mucus.
- Abdominal Cramping: Sharp lower abdominal pain, often accompanied by fever.
- Tenesmus: A painful, urgent sensation of rectal fullness where straining occurs despite an empty bowel.
- Dehydration: Fluid loss causing dizziness, dry mouth, and fatigue.
In immunocompetent adults, uncomplicated shigellosis typically resolves within 5 to 7 days, though high transmissibility warrants careful management.
The Rise of Antimicrobial Resistance: Lancet and CDC Data
Genomic surveillance indicates that sexually transmissible Shigella lineages acquire resistance far faster than classic foodborne lineages.
A genomic epidemiology study published in The Lancet Infectious Diseases by researchers at the University of Cambridge and the UK Health Security Agency (UKHSA) evaluated over 3,000 sequenced Shigella sonnei isolates. The researchers demonstrated that sexually transmissible lineages spread faster, maintained higher transmission intensity, and exhibited greater biological fitness than travel- or food-associated strains.
Over 70% of sexually transmissible isolates were resistant to at least one clinically relevant antibiotic, compared to approximately 40% of food-associated isolates. Routine antibiotic exposure within adult networks—such as azithromycin or doxycycline prescribed for other conditions—likely accelerated resistance selection in colonizing gut bacteria.
Extensively Drug-Resistant (XDR) Strains
Surveillance in the CDC Morbidity and Mortality Weekly Report (MMWR) documented the rise of extensively drug-resistant (XDR) shigellosis in the United States. XDR strains resist all five standard antimicrobial classes: azithromycin, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and ampicillin.
CDC testing revealed that the proportion of U.S. Shigella isolates with XDR profiles rose from 0% (2011–2015) to 8.5% in recent annual tracking, leaving clinicians with no proven oral antibiotic options for severe illness.
Comparing Foodborne and Sexually Transmitted Shigellosis
The table below summarizes key differences between classic foodborne outbreaks and emerging sexually transmitted strains:
| Feature | Classic Foodborne / Community | Emerging Sexually Transmitted Lineages |
|---|---|---|
| Primary Transmission | Contaminated water, food handling, daycare contact | Direct or indirect oral-anal or manual sexual contact |
| Infectious Dose | 10–100 bacterial cells | 10–100 bacterial cells |
| Resistance Profile | Largely susceptible to first-line agents | >70% resistant; rising XDR phenotype (8.5%) |
| Clinical Risk | Pediatric dehydration, institutional outbreaks | Treatment failure, persistent shedding, reinfection |
| Core Prevention | Sanitation, handwashing, safe food preparation | Barrier protection, 2-week sexual abstinence post-diarrhea |
Source: Adapted from UK Health Security Agency / University of Cambridge genomic data in The Lancet Infectious Diseases (DOI: 10.1016/S1473-3099(26)00227-6) and CDC MMWR surveillance data.
Clinical Care and Antibiotic Stewardship
The rise of drug-resistant strains alters clinical management. According to the World Health Organization (WHO), diarrhoeal diseases account for over 1.7 billion cases of illness each year globally, and unindicated antibiotic use accelerates microbial resistance.
1. Restraint in Uncomplicated Illness
Because shigellosis is typically self-limiting in immunocompetent adults, CDC guidance advises against empiric antibiotics for mild illness. Treatment focuses on oral rehydration and electrolyte replenishment. Unnecessary antibiotics provide minimal clinical benefit while driving resistance.
2. Culture and Susceptibility Testing
When severe diarrhea, bloody dysentery, high fever, or systemic symptoms occur, patients should consult a healthcare provider and disclose sexual history. The CDC recommends ordering stool cultures with antimicrobial susceptibility testing (AST). If XDR Shigella is confirmed in vulnerable individuals, infectious disease specialists coordinate targeted intravenous therapy.
3. Caution with Antidiarrheal Medications
Medical guidelines caution against antimotility drugs like loperamide in acute bacterial dysentery. By slowing bowel motility, these medications delay bacterial clearance and can worsen mucosal inflammation.
Evidence-Based Prevention: CDC Recommendations
Practical harm-reduction guidance from the CDC Shigella Prevention Guidelines includes:
- Observe a Two-Week Sexual Window: Bacterial shedding continues in stool after symptoms end. The CDC advises abstaining from all sexual activity while diarrhea persists and for at least two weeks after bowel habits normalize.
- Use Barrier Protection: Utilize dental dams or latex barriers during oral-anal contact (rimming) and condoms during anal sex. Wear disposable latex or nitrile gloves during manual-anal contact.
- Maintain Strict Hygiene: Wash hands thoroughly with soap and warm water for at least 20 seconds after using the restroom and before and after intimacy. Wash genitals and sex toys with soap and water after use.
- Occupational Precautions: Individuals with confirmed shigellosis working in food service, healthcare, or childcare should remain on medical leave until public health clearance is granted.
Study Limitations and Uncertainty
Surveillance data rely primarily on individuals seeking medical care who submit stool specimens. Mild or asymptomatic infections often go unrecorded, potentially overestimating average symptom severity while undercounting community prevalence. Additionally, optimal antibiotic protocols for XDR Shigella in severely ill patients remain an evolving area of research requiring individualized susceptibility testing.
Related Reading
- Gut Health and the Microbiome: Your Body’s Hidden Health System
- Nutrition and Immunity: Top Foods for a Strong Immune System
- Garlic and Infections: What the Evidence Actually Shows
- How a Common Gut Microbe Slashes Cholesterol and Arterial Plaque
Sources and Further Reading
- University of Cambridge and UK Health Security Agency. (2026). “The spread of sexually transmissible drug-resistant shigellosis in England: a genomic epidemiology study.” The Lancet Infectious Diseases, 26(7):e120-e131. https://doi.org/10.1016/S1473-3099(26)00227-6
- Centers for Disease Control and Prevention (CDC). (2026). “Emergence of Extensively Drug-Resistant (XDR) Shigellosis — United States, 2011–2023.” MMWR Morbidity and Mortality Weekly Report. https://www.cdc.gov/mmwr/volumes/75/wr/mm7514a1.htm
- Centers for Disease Control and Prevention (CDC). (2024). “Shigella: Prevention Guidance for Sexual Health and Daily Hygiene.” https://www.cdc.gov/shigella/prevention/index.html
- Centers for Disease Control and Prevention (CDC). (2024). “About Shigella: Transmission, Symptoms, and Clinical Overview.” https://www.cdc.gov/shigella/about/index.html
- World Health Organization (WHO). (2024). “Diarrhoeal Disease: Global Health Burden, Prevention, and Antimicrobial Resistance.” https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.